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Physical Activity Survey found that children 9-13y consumed on average
19.2 mg caffeine per day. However, little is known about caffeine con-
sumption and its impact on sleep in children. This study assessed caffeine
consumption and sleep in school aged children.
Methods: Children aged 8-12 y (10.7 ± 1.3 y, 49% male) were recruited
through South Australian schools and the community for a retrospective,
cross sectional study. Demographics, caffeine intake (a Food Frequency
Questionnaire), and daytime sleepiness (Paediatric Daytime Sleepiness
Scale) were obtained via child and parent report.
Results: Data from 230 children demonstrated daily caffeine intake
ranged between 0e64.1 mg (7.8 ± 11.7 mg). Gender did not impact
caffeine intake (p ¼ 0.97). 74% of 8 year olds consumed caffeine (8.0 ±
10.5 mg), 78% of 9 years olds (8.3 ± 9.6 mg), 72% of 10 year olds (10.1 ±
13.5 mg), 83% of 11 year olds (9.7 ± 13.4 mg) and 87% of 12 year olds
(12.6 ± 13.2 mg). Twenty-ﬁve percent (n ¼ 58) of the sample consumed
between 11.1mg (~Standard chocolate bar) and 64.1 mg (~one small
latte) of caffeine/day. Daily caffeine consumption had a signiﬁcant
relationship with age (r ¼ 0.14, p ¼ 0.03) and daytime sleepiness (r ¼
0.14, p ¼ 0.03). Children who were in the top 25% of caffeine con-
sumption had signiﬁcantly higher daytime sleepiness compared to the
remaining 75% of the sample (p ¼ 0.05).
Conclusions: These ﬁndings show that majority of children aged 8e12 y
consume caffeine. The study also shows a signiﬁcant relationship between
caffeine intake and daytime sleepiness in children, with greater caffeine
consumption associated with more daytime sleepiness.
Funding source(s): N/A.
THE METABOLISM OF DIETARY ARACHIDONIC AND EICOSAPENTAENOIC
ACIDS IN ATLANTIC SALMON AS AFFECTED BY ENVIRONMENTAL
TEMPERATURE
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E-mail address: giovanni.turchini@deakin.edu.au (G. Turchini)Background/Aims: Aquaculture is encountering sub-optimal conditions
due to changing environments. Simultaneously, shortages in marine
oils are resulting in a reduction of dietary long chain-PUFA. The effects
of water temperature and dietary arachidonic acid (ARA):EPA ratios on
the regulation of fatty acid (FA) metabolism in salmon were
investigated.
Methods: Atlantic salmon kept at optimal (10 C) and elevated (20 C)
temperature were fed one of three experimental diets. The diets had
identical FA composition with the exception of the EPA/ARA ratio,
varying from 2.4 to 0.1. The FA metabolism was assessed via the whole-
body-fatty-acid-method and selected genes expression was quantiﬁed
by qPCR.
Results: The higher temperature showed an increase in the total FA b-
oxidation (from 1,645.3 to 814.5 nmol/g/day at 20C or 10 C, respectively).
At both temperatures, the b-oxidation of SFA andMUFAwas lower in group
with highest dietary EPA supply. The higher temperature showed a
reduction in the activity and gene transcription of FA desaturases (D6fad
and D5fad) and elongase Elovl2, whereas elongase Elovl5 was not affected.
The metabolic fate of ARA was affected by temperature and dietary
treatment. Whereas, in ﬁsh held at 20 C, the metabolic fate of dietary EPA
was identical for all three treatments.
Conclusions: Temperature plays remarkable effects on EPA and ARA
metabolism. Increased dietary ARA supply, relative to EPA, is beneﬁcial in
ﬁsh held at elevated water temperatures. These ﬁndings contribute to-
wards the formulation of novel functional aquaculture diets.
Funding source(s): ARC Discovery Project.
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ROSUVASTATIN, LYCOPENE AND OMEGA-3 FATTY ACIDS: A POTENTIAL
TREATMENT FOR SYSTEMIC INFLAMMATION IN COPD
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Wood 1,2. 1Centre for Asthma and Respiratory Diseases, Hunter Medical
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Background/Aims: Chronic Obstructive Pulmonary Disease (COPD) is
characterized by lung and airway inﬂammation, resulting in loss of lung
function. Systemic inﬂammation is a feature of COPD contributing to many
associated co-morbidities. Statins, omega-3 fatty acids (DHA and EPA) and
lycopene have been shown to decrease systemic inﬂammation; this
combination has not been studied previously. The aim of this study was to
identify changes in systemic and airway inﬂammation induced by statins
and/or DHA, EPA and lycopene in COPD.
Methods: COPD patients (n ¼ 11) received rosuvastatin (20 mg/day) for 4
weeks, then a combination of rosuvastatin (20 mg/day), DHA and EPA (1.5
g/day) and lycomato (45 mg/day) for 8 weeks. Blood and sputum were
collected and lung function measured by spirometry at baseline, week 4
and 12. Plasma C-reactive protein (CRP) and IL-6 were measured using
ELISA; peripheral blood gene expression was measured using nCounter™
GX Human Inﬂammation Kit 2.
Results: Following interventions, clinical characteristics were unchanged.
Plasma IL-6 and CRP were unchanged by intervention, sputum neutrophils
were increased andmacrophages decreased by rosuvastatin (p¼ 0.020 and
p ¼ 0.015; respectively). Rosuvastatin increased LTB4R and decreased
CXCL10 and AGER blood gene expression. When lycopene and omega-3
fatty acids were added, LTB4R decreased and CXCL10 decreased to basal
levels, whilst combined intervention increased ALOX15 blood gene
expression.
Conclusions: This study shows rosuvastatin, omega-3 fatty acids and
lycopene may have anti-inﬂammatory effects systemically, but rosuvas-
tatin may increase airway neutrophils, which would be undesirable in
COPD, warranting further investigation.
Funding source(s): NHMRC, Centre for Clinical Research Excellence.
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Background/Aims: People on dialysis have a high risk of cardiovascular
disease. PUFA in particular omega-3 fatty acids are of interest in this
population due to their cardioprotective properties. The PUFA food
frequency questionnaire (FFQ) is a validated tool to measure PUFA
intake in healthy populations, but has yet to be validated in a diseased
population. The aim of this study is to validate the PUFA FFQ using the
method of triads in a population of end stage renal failure patients on
dialysis.
Methods: Participants (n ¼ 32) completed the PUFA FFQ and multiple 24
hour recalls, non-fasting blood samples were taken (n ¼ 29) for erythro-
cyte fatty acid analysis. The triangular relationship between the PUFA FFQ,
24 hour recalls and the biomarker were assessed using the method of
triads, which calculated validity coefﬁcients for PUFA. Agreement between
the two dietary methods were also assessed using Bland-Altman plots and
classiﬁcation by quintiles.
Results: The PUFA FFQ was a valid measure of all PUFA except for doco-
sapentaenoic acid (DPA) and arachidonic acid (AA). Strong validity co-
efﬁcients were found for long chain omega-3 fatty acids eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) of 0.914 (95% CI: 0.665, 0.997)
and 0.889 (95% CI: 0.706, 0.994) respectively. Bland Altman plots showed a
good level of agreement between the PUFA FFQ and the 24 hour recalls as
approximately 95% of observations were between the levels of agreement.
Conclusions: The PUFA FFQ is a valid tool for assessing PUFA intake in a
population of dialysis patients.
Funding source(s): N/A.
FAT TYPE IN PHYTOSTEROL SPREADS INFLUENCE THEIR CHOLESTEROL-
LOWERING POTENTIAL: A SYSTEMATIC REVIEW AND META-ANALYSIS
OF RCTS
